Lilly posts $23B in Q2 revenue, beating estimates by $3B as tirzepatide hits 64% of revenue; raises full year guidance to $85B–$87B.
Eli Lilly posted $23 billion in second-quarter revenues, coming in about $3 billion above analysts’ estimates.
Lilly also once again raised …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline…
Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.
Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and…
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster…
Eli Lilly's fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.
